ERCC1 isoform 3 mRNA and / or protein for use in diagnosing resistance to a therapeutic agent and method for diagnosing resistance to a therapeutic agent using this mRNA and / or protein

摘要

Circulating tumor cell (CTC) detection is widely accepted as an independent prognostic tool in solid cancer and primary and metastatic disease. Treatment failure in the treatment of the disease was indicated by a CTC that does not disappear in the course of a given treatment. However, it has been found that such prognostic information alone has limited utility because it does not help predict the therapeutic success of a particular therapeutic agent before treatment is initiated. In one aspect, an ERCC1 isoform 3 protein is provided for use in diagnosing resistance to a therapeutic agent. In another aspect, ERCC1 isoform 3 mRNA is provided for use in diagnosing resistance to a therapeutic agent.